首页 | 本学科首页   官方微博 | 高级检索  
     

前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)的安全性和有效性的Ⅲ期临床试验
引用本文:谢建兴,胡海棠,肖冬妮,解荷芝,朱成彬,杨文涛,黄显勋,何学军,梁国荣,王志刚. 前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)的安全性和有效性的Ⅲ期临床试验[J]. 中华男科学杂志, 2009, 15(11): 1049-1052
作者姓名:谢建兴  胡海棠  肖冬妮  解荷芝  朱成彬  杨文涛  黄显勋  何学军  梁国荣  王志刚
作者单位:1. 广州中医药大学第一附属医院男科,广东,广州,510405
2. 丽珠集团,广东,珠海,519020
3. 佛山市中医院男科,广东,佛山,528000
4. 广西中医学院附属瑞康医院男科,广西,南宁,530011
5. 海南省中医院男科,海南,海口,570203
6. 汕头大学第一附属医院男科,广东,汕头,515041
7. 湛江市第一中医医院男科,广东,湛江,524043
摘    要:目的:评价前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)的安全性和有效性。方法:随机、单盲、平行对照、多中心临床试验,467例受试者分为试验组349例、对照组118例。试验组前列安栓1粒,对照组野菊花栓1粒,肛内用药每晚1次,疗程28 d。以中医证候、美国国立卫生研究院慢性前列腺炎症状评分(NIH-CPSI)、主要临床症状及前列腺按摩液白细胞(EPS-WBC)计数为疗效评价指标。结果:试验组治疗结束时中医证候疗效临床控制率为4.4%、总显效率为58.0%、总有效率为90.7%,明显优于对照组的0.9%、33.1%、70.4%(P<0.025)。试验组的NIH-CPSI总分、疼痛与不适、排尿情况、生存质量评分的下降程度均较对照组明显(P<0.025)。试验组对主要临床症状尿急、会阴部等局部坠胀和局部疼痛有明显缓解作用,疗效优于对照组(P<0.05)。试验组EPS-WBC计数改善率为55.2%,明显优于对照组的32.4%(P<0.05)。试验组和对照组均未发生严重不良事件,试验药和对照药不良反应发生率低,分别为0.56%(2/349)和0.83%(1/118)。结论:前列安栓治疗慢性前列腺炎(湿热瘀血壅阻证)疗效肯定,临床用药安全性良好。

关 键 词:前列安栓  慢性前列腺炎(湿热瘀血壅阻证)  有效性  安全性  多中心随机对照试验

Safety and Efficacy of Qianliean Suppository for Chronic Prostatitis of Damp-Heat and Blood-Stasis Syndrome: A Randomized, Single-Blind, Parallel Controlled,Multi-Centered Phase m Clinical Trial
XIE Jian-xing,HU Han-tang,XIAO Dong-ni,XIE He-zhi,ZHU Cheng-bin,YANG Wen-tao,HUANG Xian-xun,HE Xue-jun,LIANG Guo-rong,Wang Zhi-gang. Safety and Efficacy of Qianliean Suppository for Chronic Prostatitis of Damp-Heat and Blood-Stasis Syndrome: A Randomized, Single-Blind, Parallel Controlled,Multi-Centered Phase m Clinical Trial[J]. National journal of andrology, 2009, 15(11): 1049-1052
Authors:XIE Jian-xing  HU Han-tang  XIAO Dong-ni  XIE He-zhi  ZHU Cheng-bin  YANG Wen-tao  HUANG Xian-xun  HE Xue-jun  LIANG Guo-rong  Wang Zhi-gang
Affiliation:XIE Jian-xing , HU Hai-tang, XIAO Dong-ni, XIE He-zhi, ZHU Cheng-bin, YANG Wen-tao, HUANG Xian-xun , HE Xue-jun, LIANG Guo-rong , Wang Zhi-gang( 1. Department of Andrology, The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, Guangdong 510405, China ; 2. Livzon Pharmaceutical Group Inc. , Zhuhai, Guangdong 519020, China; 3. Department of Andrology, Foshan Hospital of Traditional Chinese Medicine, Foshan, Guangdong 528000, China; 4. Department of Andrology, Ruikang Hospital Affiliated to Guangxi College of Traditional Chinese Medicine, Nanning , Guangxi 530011, China ; 5. Department of Andrology , Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, Hainan 570203, China; 6. Department of Andrology, The First Affiliated Hospital of Shantou University, Shantou , Guangdong 515041, China; 7. Department of Andrology , Zhanjiang First Hospital of Traditional Chinese Medicine, Zhanjiang , Guangdong 524043, China)
Abstract:Objective: To evaluate the safety and effieaey of Qianliean Suppository in the treatment of chronie prostatitis of damp-heat and blood-stasis syndrome. Methods: We conducted a randomized, single-blind, parallel-controlled, multi-centered elinical trial among 467 subjects, who were assigned to a trial group (n = 349) and a control group (n = 118), the former treated with Qianliean Suppository anally one pill per night for 28 days and the latter given Yejuhua Suppository in the same way. The efficacy was evaluated by the TCM syndrome, NIH-CPSI, main clinical symptoms and WBC count in EPS. Results: After the treatment, the total rates of recovery, excellenee and effectiveness for the TCM syndrome were 4.4%, 58.0% and 90.7% respectively in the trial group, significantly higher than 0.9%, 33.1% and 70.4% in the control group (P < 0.025). Remarkable decreases were observed in the NIHCPSI total score and the scores on pain and discomfort, voiding symptoms and quality of life in the former group compared with the latter (P < 0.025). The trial group also showed a marked alleviation of such main chronic prostatitis symptoms as urgent micturition and perineal pain and discomfort (P < 0.05), as well as an obvious improvement (55.2%) of the WBC count in EPS as compared with 32.4% in the control group (P < 0.05). No serious adverse events occurred in either of the two groups (0.56% [2/349] vs 0.83% [1/118]). Conclusions : Qianliean Suppository is safe and effective for the treatment of chronic prostatitis of damp-heat and bloodstasis syndrome.
Keywords:Qianliean Suppository  chronic prostatitis of damp-heat and blood-stasis syndrome  efficacy  safety  randomized controlled trial
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号